← Patent-cliff monitor small molecule INVOKANA CANAGLIFLOZIN
Loss of exclusivity August 2029 latest FDA-listed patent expiry
Drug detail Brand name INVOKANA Active ingredient CANAGLIFLOZIN Strength 100MG Dosage form TABLET Route ORAL Modality Small molecule FDA approval March 2013 Marketing status RX
Listed patents Patent Expires Type 7943582*PED August 2029 — 7943582 February 2029 substance, product 8513202*PED June 2028 — 7943788*PED January 2028 — 8513202 December 2027 substance, product 7943788 July 2027 substance, product
Regulatory exclusivity Code Expires PED June 2028 NPP December 2027
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.